Search Results - "BEER, Tomasz M"

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B by Sun, Yu, Campisi, Judith, Higano, Celestia, Beer, Tomasz M, Porter, Peggy, Coleman, Ilsa, True, Lawrence, Nelson, Peter S

“…Responses to anticancer therapy are hampered by several factors, and Peter S. Nelson and colleagues here identify a protective effect of the tumor…”
Get full text

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study by Schrag, Deb, Beer, Tomasz M, McDonnell, Charles H, Nadauld, Lincoln, Dilaveri, Christina A, Reid, Robert, Marinac, Catherine R, Chung, Karen C, Lopatin, Margarita, Fung, Eric T, Klein, Eric A

“…Multicancer early detection (MCED) blood tests can detect a cancer signal from circulating cell-free DNA (cfDNA). PATHFINDER was a prospective cohort study…”
Get full text

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study by Aggarwal, Rahul, Huang, Jiaoti, Alumkal, Joshi J, Zhang, Li, Feng, Felix Y, Thomas, George V, Weinstein, Alana S, Friedl, Verena, Zhang, Can, Witte, Owen N, Lloyd, Paul, Gleave, Martin, Evans, Christopher P, Youngren, Jack, Beer, Tomasz M, Rettig, Matthew, Wong, Christopher K, True, Lawrence, Foye, Adam, Playdle, Denise, Ryan, Charles J, Lara, Primo, Chi, Kim N, Uzunangelov, Vlado, Sokolov, Artem, Newton, Yulia, Beltran, Himisha, Demichelis, Francesca, Rubin, Mark A, Stuart, Joshua M, Small, Eric J

“…Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) are not well characterized in the era of modern…”
Get full text

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 by Scher, Howard I, Morris, Michael J, Stadler, Walter M, Higano, Celestia, Basch, Ethan, Fizazi, Karim, Antonarakis, Emmanuel S, Beer, Tomasz M, Carducci, Michael A, Chi, Kim N, Corn, Paul G, de Bono, Johann S, Dreicer, Robert, George, Daniel J, Heath, Elisabeth I, Hussain, Maha, Kelly, Wm Kevin, Liu, Glenn, Logothetis, Christopher, Nanus, David, Stein, Mark N, Rathkopf, Dana E, Slovin, Susan F, Ryan, Charles J, Sartor, Oliver, Small, Eric J, Smith, Matthew Raymond, Sternberg, Cora N, Taplin, Mary-Ellen, Wilding, George, Nelson, Peter S, Schwartz, Lawrence H, Halabi, Susan, Kantoff, Philip W, Armstrong, Andrew J

“…Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise…”
Get full text

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial by Kwon, Eugene D, Prof, Drake, Charles G, MD, Scher, Howard I, Prof, Fizazi, Karim, Prof, Bossi, Alberto, MD, van den Eertwegh, Alfons J M, MD, Krainer, Michael, MD, Houede, Nadine, MD, Santos, Ricardo, MD, Mahammedi, Hakim, MD, Ng, Siobhan, MD, Maio, Michele, MD, Franke, Fabio A, MD, Sundar, Santhanam, MBBS, Agarwal, Neeraj, MD, Bergman, Andries M, MD, Ciuleanu, Tudor E, Prof, Korbenfeld, Ernesto, MD, Sengeløv, Lisa, MD, Hansen, Steinbjorn, MD, Logothetis, Christopher, Prof, Beer, Tomasz M, Prof, McHenry, M Brent, PhD, Gagnier, Paul, MD, Liu, David, MD, Gerritsen, Winald R, Prof

“…Summary Background Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to…”
Get full text

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study by Scher, Howard I, Prof, Beer, Tomasz M, MD, Higano, Celestia S, MD, Anand, Aseem, MA, Taplin, Mary-Ellen, MD, Efstathiou, Eleni, MD, Rathkopf, Dana, MD, Shelkey, Julia, BS, Yu, Evan Y, MD, Alumkal, Joshi, MD, Hung, David, MD, Hirmand, Mohammad, MD, Seely, Lynn, MD, Morris, Michael J, MD, Danila, Daniel C, MD, Humm, John, PhD, Larson, Steve, MD, Fleisher, Martin, PhD, Sawyers, Charles L, MD

“…Summary Background MDV3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation…”
Get full text

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors by Fizazi, Karim, Drake, Charles G., Beer, Tomasz M., Kwon, Eugene D., Scher, Howard I., Gerritsen, Winald R., Bossi, Alberto, den Eertwegh, Alfons J.M. van, Krainer, Michael, Houede, Nadine, Santos, Ricardo, Mahammedi, Hakim, Ng, Siobhan, Danielli, Riccardo, Franke, Fabio A., Sundar, Santhanam, Agarwal, Neeraj, Bergman, André M., Ciuleanu, Tudor E., Korbenfeld, Ernesto, Sengeløv, Lisa, Hansen, Steinbjorn, McHenry, M. Brent, Chen, Allen, Logothetis, Christopher

“…The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate…”
Get full text

LSD1 activates a lethal prostate cancer gene network independently of its demethylase function by Sehrawat, Archana, Gao, Lina, Wang, Yuliang, Bankhead, Armand, McWeeney, Shannon K., King, Carly J., Schwartzman, Jacob, Urrutia, Joshua, Bisson, William H., Coleman, Daniel J., Joshi, Sunil K., Kim, Dae-Hwan, Sampson, David A., Weinmann, Sheila, Kallakury, Bhaskar V. S., Berry, Deborah L., Haque, Reina, Van Den Eeden, Stephen K., Sharma, Sunil, Bearss, Jared, Beer, Tomasz M., Thomas, George V., Heiser, Laura M., Alumkal, Joshi J.

“…Medical castration that interferes with androgen receptor (AR) function is the principal treatment for advanced prostate cancer. However, clinical progression…”
Get full text

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer by ZHU, Meng-Lei, HORBINSKI, Craig M, GARZOTTO, Mark, QIAN, David Z, BEER, Tomasz M, KYPRIANOU, Natasha

“…Recent insights into the regulation of the androgen receptor (AR) activity led to novel therapeutic targeting of AR function in prostate cancer patients…”
Get full text

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial by Loriot, Yohann, Dr, Miller, Kurt, Prof, Sternberg, Cora N, Prof, Fizazi, Karim, Prof, De Bono, Johann S, Prof, Chowdhury, Simon, PhD, Higano, Celestia S, MD, Noonberg, Sarah, MD, Holmstrom, Stefan, MSc, Mansbach, Harry, MD, Perabo, Frank G, MD, Phung, De, BSc, Ivanescu, Cristina, PhD, Skaltsa, Konstantina, PhD, Beer, Tomasz M, Prof, Tombal, Bertrand, Prof

“…Summary Background Enzalutamide significantly increased overall survival and radiographic progression-free survival compared with placebo in the PREVAIL trial…”
Get full text

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer by Tran, Chris, Ouk, Samedy, Clegg, Nicola J, Chen, Yu, Watson, Philip A, Arora, Vivek, Wongvipat, John, Smith-Jones, Peter M, Yoo, Dongwon, Kwon, Andrew, Wasielewska, Teresa, Welsbie, Derek, Chen, Charlie Degui, Higano, Celestia S, Beer, Tomasz M, Hung, David T, Scher, Howard I, Jung, Michael E, Sawyers, Charles L

“…Metastatic prostate cancer is treated with drugs that antagonize androgen action, but most patients progress to a more aggressive form of the disease called…”
Get full text

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer by Chen, William S., Aggarwal, Rahul, Zhang, Li, Zhao, Shuang G., Thomas, George V., Beer, Tomasz M., Quigley, David A., Foye, Adam, Playdle, Denise, Huang, Jiaoti, Lloyd, Paul, Lu, Eric, Sun, Duanchen, Guan, Xiangnan, Rettig, Matthew, Gleave, Martin, Evans, Christopher P., Youngren, Jack, True, Lawrence, Lara, Primo, Kothari, Vishal, Xia, Zheng, Chi, Kim N., Reiter, Robert E., Maher, Christopher A., Feng, Felix Y., Small, Eric J., Alumkal, Joshi J.

“…Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the disease. Several recent studies have identified genomic alterations in mCRPC,…”
Get full text

Molecular pathways and targets in prostate cancer by Shtivelman, Emma, Beer, Tomasz M, Evans, Christopher P

“…Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The heterogeneity of prostate cancers is evident at earlier…”
Get full text

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302) by Rathkopf, Dana E, Smith, Matthew R, de Bono, Johann S, Logothetis, Christopher J, Shore, Neal D, de Souza, Paul, Fizazi, Karim, Mulders, Peter F.A, Mainwaring, Paul, Hainsworth, John D, Beer, Tomasz M, North, Scott, Fradet, Yves, Van Poppel, Hendrik, Carles, Joan, Flaig, Thomas W, Efstathiou, Eleni, Yu, Evan Y, Higano, Celestia S, Taplin, Mary-Ellen, Griffin, Thomas W, Todd, Mary B, Yu, Margaret K, Park, Youn C, Kheoh, Thian, Small, Eric J, Scher, Howard I, Molina, Arturo, Ryan, Charles J, Saad, Fred

“…Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic…”
Get full text

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group by SCHER, Howard I, HALABI, Susan, PETRYLAK, Daniel, KANTOFF, Philip, BASCH, Ethan, KELLY, William Kevin, FIGG, William D, SMALL, Eric J, BEER, Tomasz M, WILDING, George, MARTIN, Alison, HUSSAIN, Maha, TANNOCK, Ian, MORRIS, Michael, STERNBERG, Cora N, CARDUCCI, Michael A, EISENBERGER, Mario A, HIGANO, Celestia, BUBLEY, Glenn J, DREICER, Robert

“…To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of…”
Get full text

Resistance Training Reduces Disability in Prostate Cancer Survivors on Androgen Deprivation Therapy: Evidence From a Randomized Controlled Trial by Winters-Stone, Kerri M., PhD, Dobek, Jessica C., MS, Bennett, Jill A., PhD, RN, Dieckmann, Nathan F., PhD, Maddalozzo, Gianni F., PhD, Ryan, Christopher W., MD, Beer, Tomasz M., MD

“…Abstract Objectives To investigate whether functionally based resistance exercise could improve strength, physical function, and disability among prostate…”
Get full text

Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy by Geng, Hao, Xue, Changhui, Mendonca, Janet, Sun, Xiao-Xin, Liu, Qiong, Reardon, Patrick N., Chen, Yingxiao, Qian, Kendrick, Hua, Vivian, Chen, Alice, Pan, Freddy, Yuan, Julia, Dang, Sang, Beer, Tomasz M., Dai, Mu-Shui, Kachhap, Sushant K., Qian, David Z.

“…Despite recent advances, the efficacy of androgen/androgen receptor (AR)-targeted therapy remains  limited for many patients with metastatic prostate cancer…”
Get full text

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone by Graff, Julie N, Beer, Tomasz M, Alumkal, Joshi J, Slottke, Rachel E, Redmond, William L, Thomas, George V, Thompson, Reid F, Wood, Mary A, Koguchi, Yoshinobu, Chen, Yiyi, Latour, Emile, Bergan, Raymond C, Drake, Charles G, Moran, Amy E

“…BackgroundCheckpoint inhibitors can induce profound anticancer responses, but programmed cell death protein-1 (PD-1) inhibition monotherapy has shown minimal…”
Get full text

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity by Westbrook, Thomas C., Guan, Xiangnan, Rodansky, Eva, Flores, Diana, Liu, Chia Jen, Udager, Aaron M., Patel, Radhika A., Haffner, Michael C., Hu, Ya-Mei, Sun, Duanchen, Beer, Tomasz M., Foye, Adam, Aggarwal, Rahul, Quigley, David A., Youngren, Jack F., Ryan, Charles J., Gleave, Martin, Wang, Yuzhuo, Huang, Jiaoti, Coleman, Ilsa, Morrissey, Colm, Nelson, Peter S., Evans, Christopher P., Lara, Primo, Reiter, Robert E., Witte, Owen, Rettig, Matthew, Wong, Christopher K., Weinstein, Alana S., Uzunangelov, Vlado, Stuart, Josh M., Thomas, George V., Feng, Felix Y., Small, Eric J., Yates, Joel A., Xia, Zheng, Alumkal, Joshi J.

“…The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer…”
Get full text

New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety by Beltran, Himisha, Beer, Tomasz M, Carducci, Michael A, de Bono, Johann, Gleave, Martin, Hussain, Maha, Kelly, William K, Saad, Fred, Sternberg, Cora, Tagawa, Scott T, Tannock, Ian F

“…Abstract Context Prostate cancer (PCa) is the most common noncutaneous malignancy and the second leading cause of cancer mortality amongst men in the Western…”
Get full text